CervoMed's Neflamapimod Shows NfL Reduction in nfvPPA Phase 2a
CRVO sits 42% above its 52-week low of $2.13.
Summary
CervoMed presented initial 12-week data from its Phase 2a trial of neflamapimod in nfvPPA, showing a mean reduction in plasma NfL of ~3.1 pg/mL, with a greater decline of ~5.7 pg/mL in participants with baseline NfL at or above the median. NfL is a key neurodegeneration biomarker, and the reduction contrasts with increases typically seen in natural history studies. The open-label trial enrolled 25 patients with no approved treatments available for nfvPPA. 24-week biomarker data will be presented at CTAD in November 2026, with clinical data expected in Q1 2027. This follows the company's recent 50 mg tablet formulation announcement and FDA removal of the exposure limit, supporting the neflamapimod development program.
At the time of this announcement, CRVO was trading at $3.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.7M. The 52-week trading range was $2.13 to $10.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.